Tissue-resident Immune Cell Subsets in aGVHD

Launched by NANFANG HOSPITAL, SOUTHERN MEDICAL UNIVERSITY · Nov 25, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how certain immune cells in the body may affect the development and severity of a condition called acute graft-versus-host disease (aGVHD). This condition can occur after a hematopoietic stem cell transplant, which is a procedure that helps treat certain types of cancer and blood disorders. The researchers are looking at about 40 participants, including those with different levels of aGVHD, to better understand how these immune cells work.

To join the study, participants need to be between 16 and 65 years old and must have been diagnosed with aGVHD for the first time or be receiving treatment for it. However, people with a history of certain diseases, like other cancers, or those with specific infections, mental health issues, or autoimmune diseases, may not be eligible. If you decide to participate, you will sign a consent form, and the study team will provide more information about what to expect during the trial. This research aims to improve treatment and outcomes for patients with aGVHD in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Voluntarily sign the informed consent form;
• • 2. Age 16-65 years old
• • 3. Clinically diagnosed with GVHD for the first time/receiving GVHD treatment.
• Exclusion Criteria:
• • 1. Have a history of other tumors
• • 2. With poor compliance or mental disorders
• • 3. Infected with HIV and HCV
• • 4. With uncontrolled HBV infection
• • 5. With other autoimmune diseases
• • 6. Those who are judged by the researcher to be unsuitable to participate in this study